TCR clonality and Treg frequency as predictors of outcome in stage III NSCLC treated with durvalumab.-MedSci.cn

TCR clonality and Treg frequency as predictors of outcome in stage III NSCLC treated with durvalumab.

Lau, SCM; Soleimani, S; Wong, SW; Pedersen, S; Wang, B; Elkrief, A; Patel, D; Fares, AF; Jao, K; Daaboul, N; Hakozaki, T; Bradbury, PA; Liu, G; Leighl, NB; Tsao, MS; Ohashi, PS; Pugh, TJ; Routy, B; Shepherd, FA; Sacher, AG

JOURNAL OF CLINICAL ONCOLOGY, 2020; 38 (15):

科室
- - 订阅+
  - 更多科室
工具
服务